Warning: The NCBI web site requires JavaScript to function. more...
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
Miles DW.
Breast Cancer Res. 2009;11(4):208. Epub 2009 Aug 28.
Related citations
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
Morrow PK, Zambrana F, Esteva FJ.
Breast Cancer Res. 2009;11(4):207. Epub 2009 Jul 15. Review.
Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA.
Pharmacotherapy. 2008 Oct;28(10):1255-66. Review.
Ten years of HER2-directed therapy: still questions after all these years.
Krop IE, Winer EP.
Breast Cancer Res Treat. 2009 Jan;113(2):207-9. Epub 2008 May 8. No abstract available.
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Pivot XB, Li RK, Thomas ES, Chung HC, Fein LE, Chan VF, Jassem J, de Mendoza FH, Mukhopadyay P, Roché HH.
Eur J Cancer. 2009 Nov;45(17):2940-6. Epub 2009 Aug 13.
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A, Baselga J.
Nat Clin Pract Oncol. 2008 Sep;5(9):531-42. Epub 2008 Jul 8. Review.
Current combination chemotherapy regimens for metastatic breast cancer.
Schwartz J.
Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S3-8. Review.
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA, Stein S.
Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. Epub 2008 Jul 1. Review.
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA, Patel T, Moreno-Aspitia A.
Breast Cancer Res Treat. 2010 Jun;121(2):261-71. Epub 2010 Mar 13. Review.
HER2-positive breast cancer: beyond trastuzumab.
Murphy CG, Fornier M.
Oncology (Williston Park). 2010 Apr 30;24(5):410-5. Review.
Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ, Pusztai L.
Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.
[Adjuvant chemotherapy of early stage breast cancer].
Boér K.
Orv Hetil. 2010 Feb 28;151(9):344-53. Review. Hungarian.
An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H.
Adv Ther. 2009 Mar;26(3):263-71. Epub 2009 Mar 27. Review.
Progression and treatment of HER2-positive breast cancer.
Davoli A, Hocevar BA, Brown TL.
Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. Epub 2009 Dec 20.
HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM, Reese DM, Lindsay MA, Riva A.
Clin Breast Cancer. 2002 Oct;3 Suppl 2:S75-9. Review.
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Conlin AK, Seidman AD.
Clin Breast Cancer. 2008 Jun;8(3):215-23. Review.
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe.
Piccart MJ.
Ann Oncol. 2001;12 Suppl 1:S89-94. Review.
HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL, Andersson M, Kamby C.
Cancer Treat Rev. 2009 Apr;35(2):121-36. Epub 2008 Nov 12. Review.
HER-2/neu expression in primary and metastatic breast cancer.
Lower EE, Glass E, Blau R, Harman S.
Breast Cancer Res Treat. 2009 Jan;113(2):301-6. Epub 2008 Feb 14.
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F.
Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on